Johnson & Johnson JNJ stock has risen 18.3% in the past three months, backed by improving earnings and sales, a raised 2026 outlook, strong performance from newer medicines, pipeline wins and progress ...

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings ...

Johnson & Johnson (JNJ) has been a rewarding stock to hold, up about 53% over the past year against about 17% for the S&P 500 ...

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.

Johnson & Johnson (JNJ) snapped six straight sessions of losses on Thursday, as the stock closed over 2% higher at $230.65. The New Brunswick, New Jersey-based pharma giant lost about 5% in the ...

Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth ...

The company is firing on all cylinders.

Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason ...